Searching for healthcare predictive analytics software implies there is a market of comparable products to shortlist. There is, but it is the smallest of the three ways predictive models reach patients, and the other two routes usually bypass procurement altogether.
Three Origins, Three Different Reviews
| Origin | How it arrives | Typical review | Where it goes wrong |
|---|---|---|---|
| Native to the EHR | Shipped as a configurable module in the record the organization already bought. Often switched on by informatics rather than purchased. | Configuration decision, frequently without a formal evaluation. | No local validation, no named clinical owner, and no monitoring, because nobody experienced it as a purchase. |
| Purchased point solution | A standalone product connected to streaming clinical data, surfacing alerts inside existing workflows. | Normal procurement, security review, and contracting. | Evidence is accepted as reported rather than validated locally, and post-deployment monitoring is not contracted. |
| Built internally | Developed by an in-house data science or informatics team on the organization's own data. | Highly variable. Sometimes rigorous, sometimes a project that quietly became production. | No external scrutiny, no formal change control, and key-person dependency when the builder leaves. |
The middle route is the one most organizations are equipped to handle. The first and third are where models most often reach patients without anyone having asked the validation question. A useful first exercise is not a vendor comparison, it is an inventory: list every predictive model currently influencing care in the organization and note which of the three routes it arrived by.
The Companies in This Category
AI Healthcare Now tracks the clinical decision support and predictive risk category. The count is deliberately small, and that is itself informative.
| Company | Position in the category | Profile |
|---|---|---|
| Epic | Not a standalone AI company, but the place most predictive models actually run. Ships native predictive models inside the record, which makes the EHR the real competitor to any point solution here. | Buyer profile |
| Bayesian Health | Real-time deterioration and sepsis detection built around reducing alert fatigue, with published work on prospective validation rather than retrospective accuracy alone. | Buyer profile |
A short list does not mean a small market. It reflects how often predictive models arrive inside the EHR or get built by a health system rather than sold as a visible point solution. Any market map of this category that runs to 40 companies is mostly counting analytics platforms and consultancies rather than deployed clinical prediction.
The Metrics That Actually Decide This
Area under the curve is the number that appears in every sales deck and the number that answers the fewest operational questions. It describes discrimination across all possible thresholds. Nobody deploys all possible thresholds.
| Request | Why it matters |
|---|---|
| Performance at the specific operating threshold you will deploy | This is the only performance the organization will ever experience. A strong AUC can still produce an unusable positive predictive value at the threshold that yields tolerable alert volume. |
| Positive predictive value at that threshold, given local prevalence | Determines how many alerts are correct. Prevalence differences between the validation site and yours move this number more than model quality does. |
| Expected alert volume per unit per shift | The real cost of the system is clinician attention. An 18 percent alert rate across admitted patients is a staffing problem regardless of accuracy. |
| Prospective validation in live workflow | Retrospective performance on historical records does not account for clinicians acting on the alert, documentation changing, or the model influencing its own inputs. |
| Subgroup performance, reported separately | Averaged performance hides the populations where the model fails. Ask for the breakdown that matches the population the organization serves. |
| Calibration, not just discrimination | A model can rank patients correctly while systematically over or under-stating absolute risk, which breaks any threshold tied to a clinical protocol. |
Documentation You Can Request by Name
For any predictive decision support running in or interfacing with certified health IT, the ONC HTI-1 final rule requires 31 source attributes to be made available, against 13 for evidence-based interventions. Developers were required to meet the criterion by December 31, 2024, with ongoing maintenance from January 1, 2025 and annual attestation that documentation has been reviewed.
The attribute set covers the intervention's details and output, its purpose, cautioned out-of-scope uses, development details and input features, the fairness process used in development, the external validation process, quantitative performance measures, ongoing maintenance, and the schedule for updates and continued validation. ONC frames evaluation as FAVES: fair, appropriate, valid, effective, and safe.
For Internally Built Models, Be the Regulator
In-house models escape both procurement and vendor disclosure requirements, which means the organization has to impose the discipline on itself. Hold internal work to the same standard the source attributes describe: write down the outcome variable, the training population, the fairness assessment, the external or temporal validation, the operating threshold, the monitoring plan, and the named clinical owner.
Add one requirement vendors do not face: a succession plan. A model maintained by one data scientist who leaves becomes an unowned system making clinical recommendations, and those are considerably harder to retire than to build.
Monitoring Is the Deliverable, Not the Deployment
Because models degrade without being modified, the evaluation does not end at go-live. Establish the monitoring cadence, the metrics tracked, the thresholds that trigger review, and the written conditions for switching the model off before the first alert fires. See model drift for why approval-time validation is a snapshot, and predictive analytics in healthcare for the documented failures that make this concrete.
- Inventory every predictive model influencing care, grouped by how it arrived.
- Name an accountable clinical owner for each one, including the models nobody purchased.
- Request the HTI-1 source attributes for anything running in certified health IT.
- Require performance at your operating threshold and local prevalence, not a summary accuracy figure.
- Validate locally and prospectively before the model influences care, not after.
- Contract for notice of vendor model updates and define what re-validation follows one.
- Write the off switch conditions down before go-live, while it is still a hypothetical.
Company details and category links were verified on September 15, 2026. Inclusion does not imply a commercial relationship, a product recommendation, or a comparative performance finding.